10.01.06
Indication: Weight gain and glycemic control
Source: Diabetes Care, August 2006;29(8):1826-32.
Research:
Thirty-seven subjects with type 2 diabetes were evaluated in a 40-week study. After baseline, subjects were placed on a sulfonylurea (glipizide gastrointestinal therapeutic system 5 mg/day) with placebo for three months. Subjects were then randomized in a double-blind fashion to receive either the sulfonylurea plus placebo (n = 12) or the sulfonylurea plus 1000 micrograms Cr as CrPic (n = 17) for six months. Body composition, insulin sensitivity and glycemic control were determined at baseline, end of the three-month single-blind placebo phase and end of study.
Results:
Subjects randomized to sulfonylurea/placebo, as opposed to those randomized to sulfonylurea/CrPic, had a significant increase in body weight, percent body fat, and total abdominal fat. Subjects randomized to sulfonylurea/CrPic had significant improvements in insulin sensitivity corrected for fat-free mass, GHb and free fatty acids, as opposed to sulfonylurea/placebo. According to researchers, this study demonstrates that CrPic supplementation in subjects with type 2 diabetes who are taking sulfonylurea agents significantly improves insulin sensitivity and glucose control. Further, CrPic supplementation significantly attenuated body weight gain and visceral fat accumulation compared with the placebo group.
Source: Diabetes Care, August 2006;29(8):1826-32.
Research:
Thirty-seven subjects with type 2 diabetes were evaluated in a 40-week study. After baseline, subjects were placed on a sulfonylurea (glipizide gastrointestinal therapeutic system 5 mg/day) with placebo for three months. Subjects were then randomized in a double-blind fashion to receive either the sulfonylurea plus placebo (n = 12) or the sulfonylurea plus 1000 micrograms Cr as CrPic (n = 17) for six months. Body composition, insulin sensitivity and glycemic control were determined at baseline, end of the three-month single-blind placebo phase and end of study.
Results:
Subjects randomized to sulfonylurea/placebo, as opposed to those randomized to sulfonylurea/CrPic, had a significant increase in body weight, percent body fat, and total abdominal fat. Subjects randomized to sulfonylurea/CrPic had significant improvements in insulin sensitivity corrected for fat-free mass, GHb and free fatty acids, as opposed to sulfonylurea/placebo. According to researchers, this study demonstrates that CrPic supplementation in subjects with type 2 diabetes who are taking sulfonylurea agents significantly improves insulin sensitivity and glucose control. Further, CrPic supplementation significantly attenuated body weight gain and visceral fat accumulation compared with the placebo group.